BioSpace News Archive

In a joint research effort studying the genetics of the androgen receptor in androgenetic alopecia, scientists discover a possible genetic variation that pre-disposes COVID-19 patients to develop severe symptoms.

Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report first quarter 2020 financial results on Thursday, May 7, 2020, before the market opens.

As part of the medical technology industry’s multi-front battle to combat the coronavirus (COVID-19) pandemic, today the Advanced Medical Technology Association (AdvaMed) announced the launch of a new platform (www.VentConnect.org) to connect ventilator companies with component suppliers to help quickly scale production and distribution of these vital devices.

Moleculin Biotech, Inc.,, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced securities of the Company have been placed in a temporary trading halt following notification by the US Securities and Exchange Commission.

Sientra, Inc., a diversified medical aesthetics company, announced that it will release financial results for the first quarter of 2020 after the close of trading on Monday, May 11, 2020.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 525,000 shares of BioCryst common stock on April 30, 2020 as inducements material to each employee entering into employment with BioCryst.

Axcella (Nasdaq: AXLA), today announced that its 2020 Annual Meeting of Stockholders will be held in a virtual-only format due to the continued public health impact of the coronavirus outbreak (COVID-19) and to support the health and well-being of its employees, stockholders and community.

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted eight newly-hired employees options to purchase an aggregate of 95,300 shares of Akebia’s common stock on April 30, 2020, as inducements material to each such employee’s entering into employment with Akebia.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new interim clinical data from Cohorts 1-3 of the OPTIC Phase 1 dose-ranging clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD) and provided a business update.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced financial results for the first quarter ended March 31, 2020 (“Q1 2020”).